Please ensure Javascript is enabled for purposes of website accessibility

What's Behind ImmunoGen Inc.'s Brief Dip on Tuesday?

By Cory Renauer - Feb 13, 2018 at 1:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It looks like another day of meaningless volatility for this biotech stock.

What happened

Shares of ImmunoGen Inc. (IMGN 2.44%), a clinical-stage biotech developing novel cancer drugs, slipped 10% in early morning trading despite a lack of significant news. The shares quickly recovered, narrowing the loss to 4.1% as of 1:30 p.m. on Tuesday.

So what

We really haven't heard anything new from ImmunoGen since the company released full-year 2017 results and a pipeline update that sent the stock rising yesterday. Despite today's loss, the stock has gained around 55% since the beginning of the year.

Chalk drawing of a chart that rises and then falls

Image source: Getty Images.

Without any product sales, the most important figure in last week's earnings release was the $267.1 million in cash and cash equivalents on Immunogen's balance sheet at the end of 2017. That could be more than enough to finish an ongoing pivotal trial with the company's lead candidate, mirvetuximab.

Now what

If the ovarian-cancer patients taking mirvetuximab survive significantly longer without tumor growth than those given standard chemo, Immunogen stock will soar when it reads out results of the ongoing Forward 1 trial. Immunogen doesn't expect to finish enrolling patients into the Forward 1 trial until midyear, but we'll get a sneak peek in the first quarter when independent data monitors run a futility analysis.

If the Forward 2 trial is allowed to continue -- combining mirvetuximab with several available blockbuster cancer therapies -- investors will want to look out for that data. Also later this year, investors can look for early-stage data from a couple of blood-cancer candidates that ImmunoGen picked up from Jazz Pharmaceuticals for $75 million upfront last summer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
IMGN
$4.61 (2.44%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.